In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Cingulate Inc (CING – Research Report), with a price target of $3.00. The company’s shares opened today at $0.99.
Rahman covers the Healthcare sector, focusing on stocks such as Neurosense Therapeutics Ltd., PainReform, and Virpax Pharmaceuticals. According to TipRanks, Rahman has an average return of 7.8% and a 40.63% success rate on recommended stocks.
Currently, the analyst consensus on Cingulate Inc is a Moderate Buy with an average price target of $3.00.
See the top stocks recommended by analysts >>
The company has a one-year high of $2.00 and a one-year low of $0.66. Currently, Cingulate Inc has an average volume of 160.7K.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CING in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cingulate Inc is a clinical stage biopharmaceutical company utilizing its proprietary precision timed release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes.
Read More on CING:
- Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD
- Cingulate to Present at 13th Annual LD Micro Invitational
- Cingulate, Indegene to Participate in Benzinga All Live Access Event
- Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update
- Cingulate Announces Successful Transfer of CTx-1301 (dexmethylphenidate) Proprietary PTR™ Manufacturing Processes to Societal CDMO
